Earnings Per Share, Diluted in USD/shares of Ambrx Biopharma Cayman, Inc. from 2021 to Q2 2023

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Earnings Per Share, Diluted history and change rate from 2021 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Earnings Per Share, Diluted for the quarter ending 30 Jun 2023 was -0.05 USD/shares, a 54.5% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Earnings Per Share, Diluted for 2022 was -0.29 USD/shares, a 39.6% increase from 2021.
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Earnings Per Share, Diluted (USD/shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $0 +$0.06 +54.5% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $0 +$0.03 +37.5% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q2 2022 $0 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $0 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023

Ambrx Biopharma Cayman, Inc. Annual Earnings Per Share, Diluted (USD/shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $0 +$0.19 +39.6% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023
2021 $0 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.